Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
WINT

WINT - Windtree Therapeutics, Inc. Stock Price, Fair Value and News

$0.020.00 (0.00%)
Market Closed

Price Targets

WINT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

WINT Price Action

Last 30 days

-33.3%

Last 90 days

-80%

Trailing 12 Months

-99.7%

WINT RSI Chart

WINT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

WINT Valuation

Market Cap

674.2K

Price/Earnings (Trailing)

-0.02

Price/Sales (Trailing)

10.21

EV/EBITDA

-0.01

Price/Free Cashflow

-0.13

WINT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

WINT Fundamentals

WINT Revenue

Revenue (TTM)

198.0K

WINT Earnings

Earnings (TTM)

-40.0M

Earnings Growth (Yr)

-921.27%

Earnings Growth (Qtr)

-164.18%

WINT Profitability

EBT Margin

-21970.71%

Return on Equity

344.47%

Return on Assets

-250.23%

Free Cashflow Yield

-748.22%

WINT Investor Care

Buy Backs (1Y)

60.61%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20191.4M993.0K595.5K198.0K
20181.5M1.4M1.6M1.8M
20172.2M3.2M2.3M1.5M
2016871.0K902.0K1.8M2.0M
20152.4M1.9M1.4M987.0K
2014999.8K1.6M2.2M2.8M
2013267.0K449.0K509.0K388.0K
2012000396.0K
2011000582.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Windtree Therapeutics, Inc.

WINT
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.
 CEO
 WEBSITEhttps://windtreetx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES20

Windtree Therapeutics, Inc. Frequently Asked Questions

WINT is the stock ticker symbol of Windtree Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Windtree Therapeutics, Inc. is 674.18 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check WINT's fair value in chart for subscribers.

The fair value guage provides a quick view whether WINT is over valued or under valued. Whether Windtree Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Windtree Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for WINT.

As of Wed Jan 28 2026, WINT's PE ratio (Price to Earnings) is -0.02 and Price to Sales (PS) ratio is 10.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. WINT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Windtree Therapeutics, Inc. has provided -0.859 (multiply by 100 for percentage) rate of return.